Who
Lucy Day
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, AN2 Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $22K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 May 2022
- Last trade
- 19 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —73,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —73,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —73,665 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —66,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,300 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —82,300 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —66,000 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —82,300 | filing |
| 19 Mar 2026filed 23 Mar 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —82,300 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,000 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,5785,512 at $1.01 | filing |
| 6 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,5675,512 at $1.01 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,3053,295 at $1.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | ANTX AN2 TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,2953,295 at $1.00 | filing |
News
No headline names them, or the companies they trade most, lately.